Briakinumab vs placebo
Failure to induce clinical response at end of study · induction of remission in Crohn's disease
Briakinumab may leads to lower failure to induce clinical response (Mannon 2004) CDAI ‐ (≥100 point… compared with placebo (low certainty).
1 finding from 1 review
- Anti‐IL‐12/23p40 antibodies for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes onlyRR 0.65 [0.42, 0.99]1 study · 79 participantsLow